Have a personal or library account? Click to login
Dyskalemia Prior to and After Initiation of a Fixed Dose Combination of Telmisartan and Amlodipine in Adults with Hypertension in Bangladesh Cover

Dyskalemia Prior to and After Initiation of a Fixed Dose Combination of Telmisartan and Amlodipine in Adults with Hypertension in Bangladesh

Global Heart
Volume 20 (2025): Issue 1
By: Junichi Ishigami,  Md. Mahmudul Hasan,  Aruna Sarker,  Sharmin Nahar,  Sibly Sadik Shuvo,  Mir Ishraquzzaman,  Mohammad Abdullah Al Mamun,  Md. Kalimuddin,  Sheikh Mohammad Mahbubus Sobhan,  Di Zhao,  Kunihiro Matsushita,  Lawrence J. Appel,  Sohel Reza Choudhury,  Edgar R. Miller III and  Fazila-Tun-Nesa Malik  
Open Access
|Mar 2025

References

  1. 1Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–450. DOI: 10.1161/CIRCULATIONAHA.115.018912
    Back to article
  2. 2Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet. 2016;387(10022):957–967. DOI: 10.1016/S0140-6736(15)01225-8
    Back to article
  3. 3Guerrero-Garcia C, Rubio-Guerra AF. Combination therapy in the treatment of hypertension. Drugs in Context. 2018;7:212531. DOI: 10.7573/dic.212531
    Back to article
  4. 4Kishore SP, Salam A, Rodgers A, Jaffe MG, Frieden T. Fixed-dose combinations for hypertension. Lancet. 2018;392(10150):819–820. DOI: 10.1016/s0140-6736(18)31814-2
    Back to article
  5. 5Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: A meta-analysis. The American Journal of Medicine. 2007;120(8):713–719. DOI: 10.1016/j.amjmed.2006.08.033
    Back to article
  6. 6Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clinical Journal of the American Society of Nephrology (CJASN). 2010;5(3):531–548. DOI: 10.2215/CJN.07821109
    Back to article
  7. 7Riaz BK, Islam MZ, Islam ANM, Zaman MM, Hossain MA, Rahman MM, et al. Risk factors for non-communicable diseases in Bangladesh: Findings of the population-based cross-sectional national survey 2018. BMJ open. 2020;10(11):e041334. DOI: 10.1136/bmjopen-2020-041334
    Back to article
  8. 8Hossain A, Suhel SA, Chowdhury SR, Islam S, Akther N, Dhor NR, et al. Hypertension and undiagnosed hypertension among Bangladeshi adults: Identifying prevalence and associated factors using a nationwide survey. Frontiers in Public Health. 2022;10:1066449. DOI: 10.3389/fpubh.2022.1066449
    Back to article
  9. 9Malik FT, Al Mamun MA, Choudhury SR, Ishraquzzaman M, Kalimuddin M, Huq TS, et al. May Measurement Month 2021: An analysis of blood pressure screening results from Bangladesh. European Heart Journal Supplements. 2024;26(Suppl 3):iii17–iii19. DOI: 10.1093/eurheartjsupp/suae041
    Back to article
  10. 10Lu Y, Tang O, Brady TM, Miller III ER, Heiss G, Appel LJ, et al. Simplified blood pressure measurement approaches and implications for hypertension screening: The Atherosclerosis Risk in Communities study. Journal of Hypertension. 2021;39(3):447–452. DOI: 10.1097/HJH.0000000000002682
    Back to article
  11. 11World Health Organization. WHO model list of essential medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
    Back to article
  12. 12Cohn JN, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice: A contemporary review by the National Council on Potassium in Clinical Practice. Archives of Internal Medicine. 2000;160(16):2429–2436. DOI: 10.1001/archinte.160.16.2429
    Back to article
  13. 13Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. The New England Journal of Medicine. 2004;351(6):585–592. DOI: 10.1056/NEJMra035279
    Back to article
  14. 14Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, et al. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial. European Journal of Preventive Cardiology. 2014;21(3):299–309. DOI: 10.1177/2047487313510678
    Back to article
  15. 15Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. American Heart Journal. 2004;148(1):52–61. DOI: 10.1016/j.ahj.2004.03.020
    Back to article
  16. 16Parikh RV, Nash DM, Brimble KS, Markle-Reid M, Tan TC, McArthur E, et al. Kidney function and potassium monitoring after initiation of renin-angiotensin-aldosterone system blockade therapy and outcomes in 2 North American populations. Circulation Cardiovascular Quality and Outcomes. 2020;13(9):e006415. DOI: 10.1161/CIRCOUTCOMES.119.006415
    Back to article
  17. 17Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, et al. Hyperkalemia after initiating renin-angiotensin system blockade: The Stockholm Creatinine Measurements (SCREAM) Project. Journal of the American Heart Association. 2017;6(7):e005428. DOI: 10.1161/JAHA.116.005428
    Back to article
  18. 18Reddin C, Ferguson J, Murphy R, Clarke A, Judge C, Griffith V, et al. Global mean potassium intake: A systematic review and Bayesian meta-analysis. European Journal of Nutrition. 2023;62(5):2027–2037. DOI: 10.1007/s00394-023-03128-6
    Back to article
  19. 19Ojji DB, Mayosi B, Francis V, Badri M, Cornelius V, Smythe W, et al. Comparison of dual therapies for lowering blood pressure in Black Africans. The New England Journal of Medicine. 2019;380(25):2429–2439. DOI: 10.1056/NEJMoa1901113
    Back to article
  20. 20Neldam S, Lang M, Jones R, TEAMSTA-5 Investigators T. Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: Results of the TEAMSTA-5 study. Journal of Clinical Hypertension. 2011;13(7):459–466. DOI: 10.1111/j.1751-7176.2011.00468.x
    Back to article
  21. 21Rodenburg EM, Visser LE, Hoorn EJ, Ruiter R, Lous JJ, Hofman A, et al. Thiazides and the risk of hypokalemia in the general population. Journal of Hypertension. 2014;32(10):2092–2097; discussion 2097. DOI: 10.1097/HJH.0000000000000299
    Back to article
  22. 22Volpe M, Gallo G, Tocci G. Is early and fast blood pressure control important in hypertension management? International Journal of Cardiology. 2018;254:328–332. DOI: 10.1016/j.ijcard.2017.12.026
    Back to article
  23. 23Salam A, Kanukula R, Atkins E, Wang X, Islam S, Kishore SP, et al. Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: A systematic review and meta-analysis of randomized controlled trials. Journal of Hypertension. 2019;37(9):1768–1774. DOI: 10.1097/HJH.0000000000002096
    Back to article
  24. 24Moore MN, Atkins ER, Salam A, Callisaya ML, Hare JL, Marwick TH, et al. Regression to the mean of repeated ambulatory blood pressure monitoring in five studies. Journal of Hypertension. 2019;37(1):24–29. DOI: 10.1097/HJH.0000000000001977
    Back to article
  25. 25Abernethy DR. Pharmacokinetics and pharmacodynamics of amlodipine. Cardiology. 1992;80 Suppl 1:31–36. DOI: 10.1159/000175050
    Back to article
  26. 26National Committee for Quality Assurance. Annual Monitoring for Patients on Persistent Medications (MPM) [Internet]. Washington, DC: National Committee for Quality Assurance; [cited 2023 Oct 31]. Available from: https://www.ncqa.org/annual-monitoring-for-patients-on-persistent-medications/.
    Back to article
  27. 27Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein A, Andrade SE, et al. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiology and Drug Safety. 2007;16(1):55–64. DOI: 10.1002/pds.1217
    Back to article
  28. 28Bootsma JE, Warle-van Herwaarden MF, Verbeek AL, Füssenich P, De Smet PAGM, Rikkert MGO, et al. Adherence to biochemical monitoring recommendations in patients starting with renin angiotensin system inhibitors: A retrospective cohort study in the Netherlands. Drug Safety. 2011;34(7):605–614. DOI: 10.2165/11587250-000000000-00000
    Back to article
  29. 29Porcher R, Tran VT, Blacher J, Ravaud P. Potential of stratified medicine for high blood pressure management: A modeling study using NHANES survey data. Hypertension. 2019;74(6):1420–1427. DOI: 10.1161/HYPERTENSIONAHA.119.13749
    Back to article
  30. 30Weiss J, Freeman M, Low A, Fu R, Kerfoot A, Paynter R, et al. Benefits and harms of intensive blood pressure treatment in adults aged 60 years or older: A systematic review and meta-analysis. Annals of Internal Medicine. 2017;166(6):419–429. DOI: 10.7326/M16-1754
    Back to article
  31. 31Bress AP, Greene T, Derington CG, Shen J, Xu Y, Zhang Y, et al. Patient selection for intensive blood pressure management based on benefit and adverse events. Journal of the American College of Cardiology. 2021;77(16):1977–1990. DOI: 10.1016/j.jacc.2021.02.058
    Back to article
DOI: https://doi.org/10.5334/gh.1415 | Journal eISSN: 2211-8179
Journal RSS Feed
Language: English
Submitted on: Apr 15, 2024
Accepted on: Feb 24, 2025
Published on: Mar 19, 2025
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Hypertension,
Fixed-dose combination,
Hypokalemia,
Hyperkalemia

© 2025 Junichi Ishigami, Md. Mahmudul Hasan, Aruna Sarker, Sharmin Nahar, Sibly Sadik Shuvo, Mir Ishraquzzaman, Mohammad Abdullah Al Mamun, Md. Kalimuddin, Sheikh Mohammad Mahbubus Sobhan, Di Zhao, Kunihiro Matsushita, Lawrence J. Appel, Sohel Reza Choudhury, Edgar R. Miller III, Fazila-Tun-Nesa Malik, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 20 (2025): Issue 1Next article